Michael MD - Exscientia Chief Officer
| EXAIDelisted Stock | USD 4.84 0.00 0.00% |
Executive
Michael MD is Chief Officer of Exscientia Ltd ADR
| Age | 63 |
| Phone | 44 18 6581 8941 |
| Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Exscientia Ltd ADR currently holds 18.92 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Exscientia ADR has a current ratio of 8.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Exscientia's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Verender Badial | Zura Bio Limited | 52 | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| XiaoJian Zhou | Atea Pharmaceuticals | N/A | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| David Hallett | Recursion Pharmaceuticals | 55 | |
| Frank Vollmering | Pieris Pharmaceuticals | N/A | |
| Nick MD | Century Therapeutics | N/A | |
| Janelle Gordon | Recursion Pharmaceuticals | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Kevin Leggat | Recursion Pharmaceuticals | N/A | |
| Jason Baum | Leap Therapeutics | 45 | |
| Gary MD | Sana Biotechnology | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Michael CPA | Blueprint Medicines Corp | 52 | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Alexander Azoy | Unity Biotechnology | 48 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Michael Naso | Century Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Overington, Chief Officer | ||
| Eileen JenningsBrown, Chief Officer | ||
| Ben AshwellFryer, VP Fin | ||
| Parker Moss, Executive Development | ||
| Ben Taylor, Chief CFO | ||
| CBE DPHIL, CEO Founder | ||
| Nikolaus Krall, Executive Medicine | ||
| Dan Ireland, Executive Secretary | ||
| Heather Togwell, Operations Mang | ||
| Caroline Rowland, Chief Officer | ||
| Chris Thomas, VP People | ||
| Garry Pairaudeau, Chief Officer | ||
| MarieLouise MD, Interim Lead | ||
| FRSE DPHIL, CEO Founder | ||
| David Hallett, Interim Officer | ||
| Michael MD, Chief Officer | ||
| Margo Mosley, VP Operations | ||
| Richard Law, Chief Officer | ||
| Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (10.66) % | ||||
| Current Valuation | 346.92 M | ||||
| Shares Outstanding | 130.82 M | ||||
| Shares Owned By Insiders | 25.90 % | ||||
| Shares Owned By Institutions | 20.80 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |